LBA56 - Primary efficacy analysis results from the SORCE trial (RE05): Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: An international, randomised double-blind phase III trial led by the MRC CTU at UCL

Tim Eisen ,A Ritchie,Gregers G Hermann ,Patrick Hanlon ,Axel Bex ,Eleni Frangou ,Barry W Hancock ,Laurence Albigès ,Mahesh Parmar ,James Larkin ,Elizabeth Hodgkinson ,Raphael Kaplan ,Ben Smith ,Bernard Escudier ,Steven Joniau ,Joaquim Bellmunt ,Bhavna Oza ,Ian D Davis ,Martin R Stockler ,Angela Meade

doi:10.1093/annonc/mdz394.050

LBA56 - Primary efficacy analysis results from the SORCE trial (RE05): Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: An international, randomised double-blind phase III trial led by the MRC CTU at UCL

Tim Eisen , A Ritchie + Show 18 more

Open Access

https://doi.org/10.1093/annonc/mdz394.050

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Oct 1, 2019
Citations: 13	License type: publisher-specific-oa

#Intermediate Risk Of Recurrence #Research Grant + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

LBA56 - Primary efficacy analysis results from the SORCE trial (RE05): Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: An international, randomised double-blind phase III trial led by the MRC CTU at UCL

Full Text